Prelude Therapeutics Inc.
- PRLD ยท Nasdaq
- Pharmaceutical Preparations
- Wilmington, DE
- 79 employees
- CIK 0001678660
Updated from SEC filings through
Top things to know
Executives
- Krishna Vaddi Chief Executive Officer and Director 10-K, 2026-03-10
-
Bryant Lim Chief Financial Officer 10-K, 2026-03-10 - Bryant David Lim CLO, CFO, Corp Sec. 4, 2026-02-05
-
Charles Q. Morris Chief Medical Officer 4, 2026-05-04 -
Sean P. Brusky Chief Business Officer 3, 2026-03-19 -
Andrew Combs Chief Chemistry Officer 4, 2026-02-05
Prelude Therapeutics Inc is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Wilmington, DE. It trades as PRLD on Nasdaq. Revenue was $12.1M in the fiscal year ending December 31, 2025, +73.4% from the year before. It reported about 79 employees. Krishna Vaddi is Chief Executive Officer and Director.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $12.1M 10-K, 2026-03-10 | $7.0M 10-K, 2026-03-10 | Not on file | Not on file | Not on file |
| Operating income | -$105M 10-K, 2026-03-10 | -$140M 10-K, 2026-03-10 | -$132M 10-K, 2025-03-10 | -$124M 10-K, 2024-02-15 | -$114M 10-K, 2023-03-15 |
| SG&A | $22.4M 10-K, 2026-03-10 | $28.7M 10-K, 2026-03-10 | $28.9M 10-K, 2025-03-10 | $30.7M 10-K, 2024-02-15 | $27.0M 10-K, 2023-03-15 |
| Net income | -$99.5M 10-K, 2026-03-10 | -$127M 10-K, 2026-03-10 | -$122M 10-K, 2025-03-10 | -$115M 10-K, 2024-02-15 | -$112M 10-K, 2023-03-15 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Krishna Vaddi Chief Executive Officer and Founder at Prelude Therapeutics, Founder, Orsenix | Chief Executive Officer and Director | 10-K, 2026-03-10 |
| Bryant Lim | Chief Financial Officer | 10-K, 2026-03-10 |
| Bryant David Lim | CLO, CFO, Corp Sec. | 4, 2026-02-05 |
| Charles Q. Morris | Chief Medical Officer | 4, 2026-05-04 |
| Andrew P. Combs | Named in proxy bio: Chief Chemistry Officer | DEF 14A, 2026-04-29 |
 Peggy A. Scherle | Named in proxy bio: Chief Scientific Officer | DEF 14A, 2026-04-29 |
| Sean P. Brusky | Chief Business Officer | 3, 2026-03-19 |
| Andrew Combs Chief Chemistry Officer at Prelude Therapeutics | Chief Chemistry Officer | 4, 2026-02-05 |
| Peggy Scherle Chief Scientific Officer at Prelude Therapeutics Incorporated | Chief Scientific Officer | 4, 2026-02-05 |
| Jane Huang | President, CMO | 4, 2025-10-07 |
| Victor Sandor | Board member (per proxy) bio: member of our Board | DEF 14A, 2026-04-29 |
| Paul A. Friedman | Chairman and Director | 10-K, 2026-03-10 |
| David P. Bonita, M.D. | Director | 10-K, 2026-03-10 |
| Katina Dorton | Director | 10-K, 2026-03-10 |
| Martin Babler | Director | 10-K, 2026-03-10 |
| Paul Scherer, M.D. | Director | 10-K, 2026-03-10 |
What Prelude Therapeutics Inc does
Prelude Therapeutics Incorporated ("Prelude" or the "Company") is a precision oncology company built on a foundation of drug discovery excellence to deliver novel precision cancer medicines to underserved patients. By leveraging our core competencies in cancer biology and medicinal chemistry, combined with our clinical development capabilities, we have built an efficient, drug discovery engine and the development expertise necessary to identify compelling biological targets and create new chemical entities, or NCEs, that we advance into clinical trials.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 79.8 million (as of August 6, 2026) | 10-Q, August 11, 2026 |
|---|---|---|
| Public float | $14.4M (as of June 30, 2025) | 10-K, March 10, 2026 |
| Latest proxy statement | Meeting June 9, 2026 (filed April 29, 2026) | DEF 14A, April 29, 2026 |
| Auditor | Ernst & Young LLP (Philadelphia, Pennsylvania) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| April 21, 2026 | David P. Bonita Director | Buy | 2,815,315 | $12.5M | Form 4, April 23, 2026 |
| April 21, 2026 | Capital Llc Orbimed Director | Buy | 2,815,315 | $12.5M | Form 4, April 23, 2026 |
| April 21, 2026 | Advisors Llc Orbimed Director | Buy | 2,815,315 | $12.5M | Form 4, April 23, 2026 |
| April 21, 2026 | Capital GP VI LLC OrbiMed Director | Buy | 2,815,315 | $12.5M | Form 4, April 23, 2026 |
| April 21, 2026 | Genesis GP LLC OrbiMed Director | Buy | 2,815,315 | $12.5M | Form 4, April 23, 2026 |
Recent 8-K events
- 8-K filed 2026-09-10
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-08-11
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-06-10
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-05-12
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-04-21
- Item 1.01 Entry into a material definitive agreement
- Item 8.01 Other events
- 8-K filed 2026-04-20
- Item 7.01 Regulation FD disclosure
- Item 8.01 Other events
- 8-K filed 2026-04-15
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-03-12
- Item 8.01 Other events
- 8-K filed 2026-03-10
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-02-03
- Item 7.01 Regulation FD disclosure
Frequently asked questions about Prelude Therapeutics Inc
- What does Prelude Therapeutics Inc do?
- In its own words, from Item 1 of its 10-K: "Prelude Therapeutics Incorporated ("Prelude" or the "Company") is a precision oncology company built on a foundation of drug discovery excellence to deliver novel precision cancer medicines to underserved patients. By leveraging our core competencies in cancer biology and medicinal chemistry, combined with our clinical development capabilities, we have built an efficient, drug discovery engine and the development expertise necessary to identify compelling biological targets and create new chemical entities, or NCEs, that we advance into clinical trials."
- What is Prelude Therapeutics Inc's revenue?
- $12.1M for the fiscal year ending December 31, 2025, from its 10-K filed March 10, 2026.
- Is Prelude Therapeutics Inc profitable?
- Prelude Therapeutics Inc reported net income of -$99.5M for the fiscal year ending December 31, 2025.
- How many employees does Prelude Therapeutics Inc have?
- About 79 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Prelude Therapeutics Inc?
- Krishna Vaddi, Chief Executive Officer and Director, as named in a 10-K filed March 10, 2026.
- Who is the CFO of Prelude Therapeutics Inc?
- Bryant Lim, Chief Financial Officer, as named in a 10-K filed March 10, 2026.
- Where is Prelude Therapeutics Inc headquartered?
- Wilmington, DE.
- What is Prelude Therapeutics Inc's stock ticker?
- PRLD on Nasdaq.
- What industry is Prelude Therapeutics Inc in?
- Pharmaceutical Preparations, SIC code 2834.
- What is Prelude Therapeutics Inc's website?
- preludetx.com.
- When does Prelude Therapeutics Inc report earnings next?
- November 11, 2026. Source: pg_future_events.
- Is Prelude Therapeutics Inc a public company?
- Yes. Prelude Therapeutics Inc files with the SEC under CIK 0001678660 and trades as PRLD.
- Who audits Prelude Therapeutics Inc?
- Ernst & Young LLP, Philadelphia, Pennsylvania, as named in its latest annual report (10-K).
- How many shares of Prelude Therapeutics Inc are outstanding?
- 79.8 million shares as of August 6, 2026, from its 10-Q filed August 11, 2026.
- What is Prelude Therapeutics Inc's public float?
- $14.4M as of June 30, 2025, as reported on the cover of its 10-K filed March 10, 2026.
- When is Prelude Therapeutics Inc's annual shareholder meeting?
- June 9, 2026, per its proxy statement (DEF 14A) filed April 29, 2026.
- Have Prelude Therapeutics Inc insiders traded stock recently?
- Since April 21, 2026, officers and directors reported 0 open-market sales and 5 purchases worth about $62.5M on Forms 4 and 5. The most recent: David P. Bonita (Director) bought 2,815,315 shares on April 21, 2026.